Cynosure (NASDAQ: CYNO) and Mazor Robotics (NASDAQ:MZOR) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.

Institutional and Insider Ownership

27.5% of Mazor Robotics shares are held by institutional investors. 2.9% of Cynosure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Cynosure and Mazor Robotics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cynosure N/A N/A N/A $0.65 101.49
Mazor Robotics $48.85 million 21.97 -$18.28 million ($0.79) -55.83

Cynosure has higher revenue, but lower earnings than Mazor Robotics. Mazor Robotics is trading at a lower price-to-earnings ratio than Cynosure, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Cynosure has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Mazor Robotics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

Profitability

This table compares Cynosure and Mazor Robotics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cynosure 0.70% 0.75% 0.59%
Mazor Robotics -37.66% -28.51% -22.75%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cynosure and Mazor Robotics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cynosure 0 3 4 0 2.57
Mazor Robotics 1 6 1 0 2.00

Cynosure presently has a consensus target price of $58.57, suggesting a potential downside of 11.22%. Mazor Robotics has a consensus target price of $36.60, suggesting a potential downside of 17.03%. Given Cynosure’s stronger consensus rating and higher possible upside, research analysts plainly believe Cynosure is more favorable than Mazor Robotics.

Summary

Cynosure beats Mazor Robotics on 9 of the 11 factors compared between the two stocks.

Cynosure Company Profile

Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.

Mazor Robotics Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications. Its Renaissance System and its predecessor are used in a number of spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision and cement augmentations. Furthermore the Company developed the Renaissance Brain Module, an application of its Renaissance System that provides control over the insertion of surgical instruments during brain surgery.

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.